Poor growth in medical sales for Beiersdorf:
This article was originally published in Clinica
Sales at the medical division of Beiersdorf (Germany) grew only 0.6% to DM 878 million ($593 million) in the nine months ended September 30th, 1995, compared with last year. Total turnover at Beiersdorf rose 3.2% to DM 4,077 million. At constant exchange rates sales growth would have been over 7% but the strength of the DM pushed this figure down. Domestic sales rose 7.2% to DM 1,535 million and exports increased 0.9% to DM 2,541 million. In the first nine months profits grew slightly faster than turnover. The company forecasts stronger full-year turnover growth than in the first nine months. Full-year profits are also predicted to rise at a greater rate than turnover.
You may also be interested in...
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.